A cluster randomized trial of Visitect CD4 Advanced Disease platform among outpatients with advanced HIV disease in Uganda.

ABSTRACT:

Introduction

Despite significant progress in HIV care globally, a persistent 30-40% of people present with advanced HIV disease with ≤200 CD4 cells/µl. The Visitect CD4 Advanced Disease platform is a point-of-care CD4 test being implemented in resource-limited settings. We sought to assess clinical outcomes of survival and retention-in-care among people with advanced HIV disease based on CD4 testing modality.

Methods

We performed a cluster randomized clinical trial to evaluate the Visitect CD4 compared with onsite standard laboratory-based CD4 testing. The trial was conducted at 16 outpatient HIV clinics in Uganda. Those identified with CD4≤200 cells/µl received a standardized package of care for advanced HIV disease. The primary outcome was 24-week survival with retention-i

SUBMITTER: Nalintya E 

PROVIDER: S-EPMC12824445 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature